No Relationship of Anti-Androgens to Alzheimer’s Disease or Cognitive Disorder in the MedWatch Database

Steven Lehrer\textsuperscript{a,}*, Peter H. Rheinstein\textsuperscript{b} and Kenneth E. Rosenzweig\textsuperscript{a}

\textsuperscript{a}Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

\textsuperscript{b}Severn Health Solutions, Severna Park, MD, USA

Accepted 26 February 2018

Abstract

\textbf{Background}: Two large studies suggest that risk is not increased. But other studies have found increased risk of Alzheimer’s disease and impaired cognition.

\textbf{Objective}: To determine whether androgen deprivation therapy increases the risk of impaired cognition or Alzheimer’s disease in men with prostate cancer.

\textbf{Methods}: We used data from MedWatch, the Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program. Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of a public database. We used the online tool OpenVigil 2.1 to query the database. OpenVigil calculates proportional reporting ratios (PRRs) from adverse drug reaction reports to determine whether the combination of drug and adverse event are related. For example, $\text{PRR} = 2$ indicates that the adverse reaction is two times more frequent in users of the drug than in the general population.

\textbf{Results}: We analyzed adverse event reporting data for these androgen-deprivation drugs: The luteinizing hormone releasing hormone (LHRH) agonists leuprolide, goserelin triptorelin, histrelin; the anti-androgens flutamide, nilutamide, enzalutamide, and bicalutamide; the LHRH antagonist degarelix; the CYP17 inhibitor abiraterone; the anti-fungal ketoconazole, which is also an anti-androgen administered to men with advanced prostate cancer.

\textbf{Conclusion}: Our analysis of FDA MedWatch adverse event data reports does not support the idea that androgen deprivation therapy \textit{per se} is associated with Alzheimer’s disease or cognitive dysfunction. Perhaps the prostate cancer itself, or the stress it imposes on the man who has it, may be detrimental to mood and intellect, increasing susceptibility to Alzheimer’s disease and cognitive disorder.

Keywords: Alzheimer’s disease, androgen deprivation, cognitive, MedWatch, OpenVigil

INTRODUCTION

Does androgen deprivation therapy (ADT) increase the risk of impaired cognition or Alzheimer’s disease in men with prostate cancer? Three studies suggest that risk is not increased [1–3]. But other studies have found increased risk of Alzheimer’s disease and impaired cognition [4, 5]. In the present study, we analyzed FDA MedWatch adverse event reporting data for these androgen-deprivation drugs:

- The luteinizing hormone releasing hormone (LHRH) agonists leuprolide, goserelin triptorelin, histrelin;
The anti-androgens flutamide, nilutamide, enzalutamide, and bicalutamide; the LHRH antagonist degarelix; the CYP17 inhibitor abiraterone; the anti-fungal ketoconazole, which is also an anti-androgen administered to men with advanced prostate cancer.

We determined the frequency of Alzheimer’s disease and cognitive disorder as adverse events reported after use of these medications, and whether Alzheimer’s disease or cognitive disorder was significantly related to their use.

METHODS

We analyzed data from MedWatch, the Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program [6]. MedWatch was organized in 1993 to collect data regarding adverse events in healthcare. An adverse event is any undesirable experience associated with the use of a medical product. The MedWatch system collects reports of adverse reactions and quality problems, primarily due to drugs and medical devices, but also for other FDA-regulated products (e.g., dietary supplements, cosmetics, medical foods, and infant formulas).

MedWatch offers a choice between a voluntary reporting form, designed primarily for health care professionals and the general public, and a mandatory adverse event reporting service (AERS) form, available to manufacturers, importers, and medical product user facilities that manage and store medical products. The latter group is required by law to submit the mandatory form immediately upon discovery of a product malfunction. Printable mail-in forms are available as an alternative to the online submission system [7].

A MedWatch report of an adverse event does not establish causation. For any given report, there is no certainty that the drug in question caused the reaction. The adverse event may have been related to the underlying disease being treated, another drug being taken concurrently, or something else.

Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of a public database. We used the online tool OpenVigil 2.1 to query the database [8, 9]. OpenVigil data are exclusively from FDA and MedWatch, not from social media [10]. OpenVigil calculates proportional reporting ratios (PRRs) from adverse drug reaction reports to determine whether the combination of drug and adverse event are related, using the criteria of Evans et al. [11]. PRR = 2 indicates that the adverse reaction is two times more frequent in users of the drug than in the general population. According to the criteria of Evans et al. [11] for 3 adverse events, chi-squared > 4 (p = 0.05), PRR > 2 indicate that the adverse reaction and the drug are related.

Ketoconazole, an anti-fungal, blocks production of androgens. Ketoconazole is most often used to treat men just diagnosed with advanced prostate cancer; it quickly reduces testosterone levels and can be administered if other forms of hormone therapy are no longer effective. To assess the relationship of ketoconazole and Alzheimer’s disease in prostate cancer, we restricted the OpenVigil analysis to men over age 60.

The MedWatch data are imperfect, with under- and over-reporting, missing denominator (that is, number of doses for a drug), wrong, duplicate and/or missing data in the database [8]. Consequently the total number of adverse event reports for all drugs and/or the drug in question from OpenVigil can vary slightly from drug to drug and for different adverse events related to the same drug. The flawed MedWatch data has presented a problem that all analytical software, such as OpenVigil, has been forced to confront [12]. For example, the OpenVigil report for leuprolide indicates that MedWatch had received a total of 8,803 adverse event reports relevant to leuprolide. Of these, 6 were of dementia Alzheimer’s type (0.068%). In comparison, for all drugs in MedWatch there were 1988 reports of Alzheimer’s disease among a total number of 3,792,386 adverse events. But in the case of cognitive disorder, 18 adverse event reports were of leuprolide and cognitive disorder (0.20%). In comparison, for all drugs in MedWatch there were 10,052 reports of cognitive disorder among a total number of 3,794,374 adverse events.

RESULTS

Data to evaluate the criteria of Evans et al. for Alzheimer’s disease and androgen deprivation drugs are listed in Table 1. Alzheimer’s disease, according to the criteria, is unrelated to any of the drugs.

Data to evaluate the criteria of Evans et al. for cognitive disorder disease and androgen deprivation drugs are listed in Tables 1 and 2. Cognitive disorder, according to the criteria, is unrelated to any of the drugs.
Table 1

Data to evaluate the criteria of Evans et al. for Alzheimer’s disease and androgen deprivation drugs

| Drug       | Drug All events | Alzheimer’s % | All drugs Total events | Alzheimer’s % | Chi-Sq+Yates | PRR 95% CI lower bound | PRR 95% CI upper bound |
|------------|-----------------|---------------|------------------------|---------------|--------------|------------------------|------------------------|
| Leuprolide | 8,803           | 6             | 3,792,386             | 1,998         | 0.17         | 1.3                    | 0.58                   | 2.9                     |
| Goserelin  | 2,877           | 3             | 3,800,300             | 1,991         | 0.65         | 1.99                   | 0.64                   | 6.17                    |
| Triptorelin| 260             | 0             | 3,802,890             | 1,994         | 0.97         | 0                      | 0                      | 0                       |
| Histrelin  | 287             | 0             | 3,802,917             | 1,994         | 0.81         | 0                      | 0                      | 0                       |
| Degarelix  | 395             | 0             | 3,802,782             | 1,994         | 0.41         | 0                      | 0                      | 0                       |
| Abiraterone| 1,941           | 2             | 3,801,236             | 1,992         | 0.23         | 0.97                   | 0                      | 0                       |
| Bicalutamide| 2,874          | 2             | 3,800,390             | 1,992         | 0.01         | 1                     | 0.34                   | 5.48                    |
| Flutamide  | 292             | 0             | 3,802,885             | 1,994         | 0.79         | 0                      | 0                      | 0                       |
| Nilutamide | 52              | 0             | 3,803,125             | 1,994         | 8.2          | 0                      | 0                      | 0                       |
| Enzalutamide| 52             | 0             | 3,803,125             | 1,994         | 8.2          | 0                      | 0                      | 0                       |
| Ketoconazole| 251            | 0             | 351,960               | 368           | 2.2          | 0                      | 0                      | 0                       |
| Total      | 18,084          | 13            | 0.072                  |               |              |                        |                        |                         |

Alzheimer’s disease, according to these criteria (n>3 adverse events, chi-squared > 4, PRR > 2), is unrelated to any of the drugs. The MedWatch data are imperfect, with under- and over-reporting, missing denominator (that is, number of doses for a drug), wrong, duplicate and/or missing data in the database. Consequently the total number of adverse event reports for all drugs and/or the drug in question from OpenVigil can vary slightly from drug to drug and for different adverse events related to the same drug. *Ketoconazole analysis restricted to males over 60.

Proportional reporting ratios for Alzheimer’s disease and cognitive disorder for the individual drugs are summarized in Fig. 1.

We performed a second analysis looking at all androgen deprivation drugs taken together compared to the entire MedWatch database. Because reports of Alzheimer’s disease in patients below the age of 60 are uncommon, we restricted the analysis to male patients over 60.

MedWatch received a total of 6,041 adverse event reports for all androgen deprivation drugs. Of these, 7 were of dementia Alzheimer’s type (0.12%). In comparison, for all drugs in MedWatch there were 659 reports of cognitive disorder among 346,170 adverse events. Chi-Squared with Yates’ correction: 1.37. PRR and 95% confidence interval (lower bound; upper bound): 0.61 (0.29; 1.28). According to the criteria of Evans et al. the combination of anti-androgenic drugs and cognitive disorder is probably not related.

DISCUSSION

Testosterone is related to cognition. Sex hormones affect brain development. Androgens modify neural activity needed for learning and memory, are neuroprotective during aging, protect against Alzheimer’s disease in mouse models [13] and, hypothetically, humans [14]. The androgen receptor directly mediates neuroprotection [15]. But testosterone apparently does not affect those parts of the brain that demonstrate sex differences in performance; and no one knows whether testosterone is necessary to maintain intellect throughout life [16].

Testosterone deprivation may impair memory in older men [17]; while testosterone supplementation can augment memory and spatial perception. Studies of prostate cancer demonstrate that androgen
deprivation drugs adversely affect cognition [18], which returned to baseline when drugs were withdrawn [19]. Moreover, LHRH agonist use as compared with no use in men with prostate cancer was associated with a decreased risk of death from Alzheimer’s disease [20].

Nevertheless, two large studies failed to confirm any effect of androgen deprivation on cognition or Alzheimer’s disease in men with prostate cancer [1, 2]. Our analysis of FDA MedWatch adverse event data reports, likewise, does not support the idea that androgen deprivation therapy per se is associated with Alzheimer’s disease or cognitive dysfunction. Perhaps the prostate cancer itself, or the stress it imposes on the man who has it, may be detrimental to mood and intellect, increasing susceptibility to Alzheimer’s disease. Indeed, proneness to psychological distress elevates Alzheimer’s disease risk [21]. Cancer-related cognitive dysfunction, particularly subjective cognitive dysfunction, has been attributed to chemotherapy, hormone therapy, fatigue, mood disturbance and cancer itself, even without metastases or a primary brain tumor [22, 23]. But we cannot rule out a subgroup of prostate cancer patients that might be vulnerable, perhaps men homozygous for the apoE4 allele.

A weakness in our MedWatch analysis is that it represents an uncontrolled epidemiological study. A major improvement in design would be a prospective randomized trial. A greater design improvement would be repeated measures comparing the same subject under different conditions.

Does androgen deprivation result in Alzheimer’s disease and cognitive dysfunction in prostate cancer patients? More studies are needed for a definite answer.

### Table 2
Data to evaluate the criteria of Evans et al. for cognitive disorder disease and androgen deprivation drugs: Cognitive disorder, according to these criteria, is unrelated to any of the drugs

| Drug        | All drugs | Cognitive | Chi-Sq+Yates | PRR lower bound | PRR upper bound |
|-------------|-----------|-----------|--------------|----------------|----------------|
| Leuprolide  | 3,794,374 | 10,052    | 1            | 0.77            | 0.486          | 1.22           |
| Goserelin   | 3,800,300 | 10,066    | 1.28         | 0.52            | 0.197          | 1.4            |
| Triptorelin | 3,802,917 | 10,070    | 0.05         | 0               | 0              | 0              |
| Histrelin   | 3,802,890 | 10,070    | 0.089        | 0               | 0              | 0              |
| Degarelix   | 3,802,782 | 10,069    | 0.2          | 0.96            | 0.14           | 6.8            |
| Abiraterone | 3,801,236 | 10,069    | 2.58         | 0.19            | 0.027          | 1.38           |
| Bicalutamide| 3,800,390 | 10,068    | 3.24         | 0.27            | 0.068          | 1.08           |
| Flutamide   | 3,802,885 | 10,070    | 0.097        | 0               | 0              | 0              |
| Nilutamide  | 3,803,125 | 10,070    | 0.96         | 0               | 0              | 0              |
| Enzalutamide| 3,803,125 | 10,070    | 0.96         | 0               | 0              | 0              |
| Ketoconazole| 351,960   | 665       | 0.001        | 2.11            | 0.3            | 14.9           |

*Ketoconazole analysis restricted to males over 60.

### REFERENCES

[1] Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA (2017) Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. *Cancer* 123, 237-244.

[2] Baik SH, Kury FSP, McDonald CJ (2017) Risk of Alzheimer’s disease among senior medicare beneficiaries treated with androgen deprivation therapy for prostate cancer. *J Clin Oncol* 35, 3401-3409.

[3] Nead KT, Sinha S, Nguyen PL (2017) Androgen deprivation therapy for prostate cancer and dementia risk: A systematic review and meta-analysis. *Prostate Cancer Prostatic Dis* 20, 259-264.

[4] Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, Shah NH (2016) Androgen deprivation therapy and future Alzheimer’s disease risk. *J Clin Oncol* 34, 566-571.

[5] Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Studier WM (2010) Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. *Crit Rev Oncol Hematol* 75, 152-159.

[6] Kessler DA, Natanblut S, Kennedy D, Lazar E, Rheinstein P, Anello C, Barash D, Bernstein I, Bolger R, Cook K (1993) Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. *JAMA* 269, 2765-2768.

[7] Craigle V (2007) MedWatch: The FDA safety information and adverse event reporting program. *J Med Libr Assoc* 95, 224.

[8] Bohm R, Hooker J, Cascorbi I, Herdgen T (2012) OpenVigil—free eyeballs on AERS pharmacovigilance data. *Nat Biotechnol* 30, 137-138.

[9] Bohm R, von HL, Herdgen T, Klein HJ, Bruhn O, Petri H, Hooker J (2016) OpenVigil. *PLoS One* 11, e0157753.

[10] Coloma PM, Becker B, Sturkenboom MC, van Mulligen EM, Kors JA (2015) Evaluating social media networks in medicines safety surveillance: Two case studies. *Drug Saf* 38, 921-930.

[11] Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf* 10, 483-486.
[12] Hauben M, Reich L, DeMicco J, Kim K (2007) ‘Extreme duplication’ in the US FDA Adverse Events Reporting System database. Drug Saf 30, 551-554.

[13] Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ (2006) Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer’s disease. J Neurosci 26, 13384-13389.

[14] Pike CJ, Carroll JC, Rosario ER, Barron AM (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 30, 239-258.

[15] Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A (2001) Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem 77, 1319-1326.

[16] Janowsky JS (2006) Thinking with your gonads: Testosterone and cognition. Trends Cogn Sci 10, 77-82.

[17] Bussiere JR, Beer TM, Neiss MB, Janowsky JS (2005) Androgen deprivation impairs memory in older men. Behav Neurosci 119, 1429-1437.

[18] Gonzalez BD, Jim HSL, Booth-Jones M, Small BJ, Sutton SK, Lin HY, Park JY, Spiess PE, Fishman MN, Jacobsen PB (2015) Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: A controlled comparison. J Clin Oncol 33, 2021-2027.

[19] Cherrier MM, Aubin S, Higano CS (2009) Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 18, 237-247.

[20] D’Amico AV, Bracchioforte MH, Moran BJ, Chen MH (2010) Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord 24, 85-89.

[21] Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA (2003) Proneness to psychological distress is associated with risk of Alzheimer’s disease. Neurology 61, 1479-1485.

[22] Biegler KA, Chaoul MA, Cohen L (2009) Cancer, cognitive impairment, and meditation. Acta Oncol 48, 18-26.

[23] Welfel JS, Kayl AE, Meyers CA (2004) Neuropsychological dysfunction associated with cancer and cancer therapies: A conceptual review of an emerging target. Br J Cancer 90, 1691-1696.